Current findings are derived primarily from preclinical and experimental research settings
Neurogastroenterol Motil 30(7):e13313-e Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB et al (2018) LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
But NAD side effects are frequent on this method because ussually it is administered too quickly
Beyond BMI, providers evaluate baseline glucose metabolism, liver and kidney function, family history of thyroid or pancreatic disease, and current medications that could interact with GLP-1 receptor agonists
D.PachecoB
Explore our comprehensive library at visiongain.com Press & Media Enquiries For commentary, data requests or interview enquiries, please contact: [email protected]